Europe IVD Market by Technology (Hepatitis C, Hepatitis B, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV), Covid- 19), Tissue Diagnostics (H&E Stains, Special Stains, Advanced Stains, Digital Scanners), Sequencing (Clinical, NIPT and Research Use Only), Geography (Europe,), and forecast to 2029

Purchase Option

$ 3100
$ 4600
$ 6900

Europe IVD Market size was valued at Euro 1,765.7 million in 2022 and is poised to grow at a significant CAGR of 4.6% over 2023–2029. The in vitro diagnostics (IVD) market in Europe plays a critical role in the healthcare industry by providing valuable information for disease diagnosis, treatment decisions, and patient monitoring. IVD encompasses a wide range of tests and technologies that are performed on samples such as blood, tissue, or urine, outside the body to aid in disease detection and management. In Europe, the IVD market is highly developed and encompasses various segments, including molecular diagnostics, tissue diagnostics, and sequencing. Tissue diagnostics is a crucial segment of the Europe IVD market. It involves the examination of tissue samples to diagnose diseases, assess treatment effectiveness, and determine prognosis. Tissue diagnostics play a vital role in the detection and management of various conditions, including cancer, autoimmune disorders, and infectious diseases. The Europe IVD market has witnessed substantial growth in recent years, driven by factors such as the increasing prevalence of chronic and infectious diseases, a growing elderly population, technological advancements, and the need for personalized medicine. The market is characterized by the presence of both multinational corporations and a significant number of local and regional players, fostering competition and innovation.

Europe IVD Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.6%

Largest Market

N/A

Fastest Growing Market

N/A
Europe IVD Market Dynamics

One of the key drivers propelling the growth of the Europe IVD market is the increasing prevalence of chronic and infectious diseases. The region is witnessing a rise in the incidence of conditions such as cancer, cardiovascular diseases, diabetes, and respiratory disorders. This surge in disease burden necessitates accurate and efficient diagnostic tools to enable early detection, and treatment selection. The Europe IVD market has been propelled by continuous technological advancements and innovations. Advanced platforms and techniques, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), have revolutionized the diagnostic landscape, enabling the detection and characterization of diseases at the genetic level. Governments and healthcare organizations in Europe are increasingly focusing on preventive healthcare to reduce the burden of diseases and improve overall health outcomes. Diagnostic tests play a crucial role in preventive healthcare by enabling early detection, risk assessment, and disease screening. Molecular diagnostics, with their ability to identify disease markers before symptoms manifest, have gained prominence in preventive healthcare strategies, driving the market growth. Compliance with complex and evolving regulatory requirements, such as the EU's In Vitro Diagnostic Regulation, poses a challenge for manufacturers, especially small and medium-sized enterprises. Obtaining reimbursement for IVD tests from healthcare systems can be difficult due to varying policies and lengthy processes. Additionally, the lack of standardization in tests and reporting methodologies within Europe can affect the reliability and comparability of IVD results.

Europe IVD Market Segmentation

By Technology
  • Molecular Diagnostics
    • Hepatitis B
    • Hepatitis C
    • Human Immunodeficiency Virus (HIV)
    • Cytomegalovirus (CMV)
    • Epstein–Barr virus (EBV)
    • Tuberculosis
    • Sexually Transmitted Diseases (STDs)
    • Hospital Acquired Infections
    • Respiratory Infections
    • Human Papillomavirus (HPV)
    • Covid- 19
By Technology
  • Tissue Diagnostics
    • H&E Stains
    • Special Stains
    • Advanced Stains
    • Digital Scanners
By Technology
  • Sequencing
    • Clinical
    • NIPT
    • Research Use Only
By Region
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Republic of Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden

Frequently Asked Questions

The Europe IVD market is valued at Euro 1,765.7 million in 2022 and is poised to grow at a significant CAGR of 4.6 % over 2023–2029.

QIAGEN, Bio-Rad Laboratories, Interlab Services, Roche Diagnostics, Thermofisher Scientific, Seegene, Inc., Cepheid, Inc., Abbott, Inc., Illumina, Inc., Dako, Leica, and Abbott

Tissue-based diagnostic testing continues to serve as one of the gold standards for cancer diagnosis. There is no other technology that can capture the disease's biological background and essential characteristics that influence patient outcomes.

Sequencing is a set of procedures for determining the fundamental structure of an unbranched biopolymer (DNA, RNA, protein, or carbohydrate), which results in a symbolic linear representation of the monomeric subunits that summarizes most of the molecule's atomic structure. NIPT is Non-invasive prenatal testing (NIPT), is a method of determining the risk to the fetus will be born with certain genetic abnormalities.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • QIAGEN
  • Bio-Rad Laboratories
  • Interlab Services
  • Roche Diagnostics
  • Thermofisher Scientific
  • Seegene, Inc.
  • Cepheid, Inc.
  • Abbott, Inc.
  • Illumina, Inc.
  • Dako
  • Leica
  • Abbott

Adjacent Markets